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Several extensive small molecule screens
against growing Plasmodium falciparum have
recently been published [1–3] and thou-
sands of hit structures are now publicly
available. This represents a large majority
of the drug-like chemical diversity cur-
rently available for screening and hence
delineates the currently drugable target
space of P. falciparum, since the ‘‘drug-
ability’’ term includes an ‘‘availability’’
concept. From a chemical standpoint,
some hits may look like bona fide drug
leads while others more like chemical
probes for target identification, but if the
hit set is globally biased for any physico-
chemical property, relative to the starting
screening libraries, it is the microorganism
that ‘‘selected’’ for it. We can ask next
what is the nature of the bias, and whether
the chemical diversity identified in the
screens is a reasonable representation of
the chemotypes needed to inhibit the
essential and potentially drugable targets
in the pathogen. The usual answer to that
question is ‘‘surely not’’, but why?
The starting compound libraries are
purposely biased to fit into the ‘‘ADME
space’’ for orally bioavailable compounds
[4,5] and by the practicalities of synthetic
chemistry. Screening libraries at compa-
nies also reflect their interest in certain
human targets, although in GlaxoSmith
Kline’s case half of the starting compounds
were purchased from outside vendors, and
other published hit sets contain commer-
cial compounds only [2,3]. It is difficult to
estimate what coverage of target space has
been achieved with the published struc-
tures. Nobody knows the total number of
potentially drugable targets in Plasmodium,
but as a first approximation we can use the
figure of 400 predicted eukaryotic core
essential genes [6]. Some gene functions
will not be drugable, but others not
belonging to the core set may be indis-
pensable in the human host cell.
In principle we could use the chemical
families identified in the screens to roughly
estimate the number of therapeutically
relevant targets, meaning those that can be
lethally affected by achievable concentra-
tions of drug-like compounds. However, in
the authors’ view, establishing a one-to-
one correlation would be unsatisfactory, as
we would need to assume that each
chemical family inhibits a different target.
Chemoinformatic tools to classify com-
pounds leave plenty of room to make each
classification subjective. Chemists accept
as a fact of life that the same compound
can be classified in either one of two, or
even more, related chemical families. That
may carry less consequence in terms of
chemical thinking, but in the context of
this discussion, it means we cannot reliably
establish a univocal correspondence be-
tween chemical families and individual
targets. During our ongoing analysis of the
Tres Cantos Antimalarial Set (TCAMS)
[1] (deposited at https://www.ebi.ac.uk/
chemblntd together with similar sets from
St. Jude Children’s Research Hospital and
Novartis-GNF), we are finding that com-
pounds in the same chemical family show
different parasitological properties. Some
inhibit an identified essential enzyme while
others do not, and some exhibit a delayed-
death phenotype, but not so their fellow
class members. Conversely, different
chemical families are being found to kill
parasites through inhibition of the same
target. These findings show that a one
chemical family–one target correlation
cannot be reliably established when based
on purely chemical criteria.
Computational tools to analyze hit sets
need to be biologically informed in order
to be useful for generating target hypoth-
eses. It is not helpful simply trying to
define ‘‘the’’ physicochemical properties
common to antimalarial hits from whole-
cell screens. One would not expect all
binding sites for small ligands in a
microorganism to have common features,
and that they will differ between taxo-
nomic divisions. So unless there is one, or
very few, prevailing killing mechanism for
most compounds in the set, the dominant
requirements common to all hits against a
given pathogen will be those broadly
related to cellular transport (influx, efflux,
and intracellular accumulation). Biological
information must be layered on top of the
chemical clustering to make it useful for
investigating the target space of a patho-
gen. Computational exercises can estimate
chemical similarities between compounds
in the set and known ligands of specific
proteins, or estimate the physicochemical
complementarity between compounds and
binding sites in proteins with known or
modelled structures. Given the large gaps
in the basic knowledge of Plasmodium, all
these analyses require a great deal of
extrapolation and lots of modelling, an-
choring target predictions to very few
known structures and making them highly
operator dependent. The approach has
recently claimed some successes [7–9], but
to date most practitioners admit that truly
novel insights are usually needles in a
haystack of already known or strongly
suspected targets.
Sets of whole-cell hits should be re-
screened for specific modes of action. Even
with the small numbers of compounds in
such sets, single target screens are proba-
bly not practical given the effort required
to validate individual targets and develop
robust assays, and attempts in that direc-
tion have failed to produce useful results so
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munity could come up with broad triaging
assays, somewhat parallel to what the yeast
community undertook to find functions for
genes in the then newly sequenced ge-
nome of Saccharomyces cerevisiae [11]. They
collectively generated and exchanged well-
defined mutant strains that were tested in
simple assays to cluster the affected genes
into broad phenotypic groups. TCAMS is
being screened against P. falciparum under
in vitro conditions that make the parasite
resistant to inhibition of certain metabolic
pathways, allowing identification of groups
of compounds inhibiting any target in
those pathways (unpublished data). But the
malaria community has developed or is
developing wider and more informative
assays able to detect interference with
complex processes, such as protein export
to the red cell surface (A. Cowman,
personal communication). Most of those
assays are complex and not amenable to
high throughput screening, but they are
certainly approachable with the tens of
thousands of existing whole-cell hits. It
may not be possible to assign individual
targets to all compounds, particularly to
those hitting more than one target, but
validating a given pathway or cellular
process as amenable to pharmacological
intervention will still be useful. A chemical
genomics program to elucidate the mode
of action of the published antimalarial hits
is possible today but would need the kind
of community commitment, leadership,
and funding that enabled the functional
analysis of model organisms through
coordination of tasks and resources and
the sharing of data and reagents. We
would support such an initiative by
catalysing it and as active members of a
reagent and information-sharing consor-
tium if it were formed. Participating
groups could make use of existing public
repositories such as the Malaria Research
and Reference Reagent Resource Center
(MR4; http://www.mr4.org/). Funding
for the fly, worm, and yeast functional
genomics efforts was largely justified by
their potential contributions to human
health. Now we have the tools to identify
the drugable genome of the pathogen
responsible for the most deadly form of
malaria, as defined by currently existing
drug-like molecules. In an ideal world such
a project should not need additional
justification, but we hope the malaria
community will rise to the challenge in
today’s funding environment.
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